Table 1.
Association of Investigated Polymorphisms with Event-Free and Overall Survival in Osteosarcoma Patients
| Event-free survival | Overall survival | ||||||
|---|---|---|---|---|---|---|---|
| Gene | Polymorphism | MAF | GenotypeCT+TT | HR (95% CI)0.85 (0.34–2.15) | pa0.729 | HR (95% CI)0.49 (0.22–1.11) | pa0.089 |
| REV1 | rs3087403 | CC | Reference | Reference | |||
| p.Val138Met | 0.24 | CT+TT | 3.79 (1.53–9.35) | 0.004 | 4.44 (1.92–10.27) | <0.001 | |
| rs3087386 | GG | Reference | Reference | ||||
| p.Phe257Serb | 0.45 | GA+AA | 1.19 (0.42–3.39) | 0.744 | 1.96 (0.72–5.33) | 0.189 | |
| rs3087399 | TT | Reference | Reference | ||||
| p.Asn373Ser | 0.22 | TC+CC | 1.38 (0.59–3.26) | 0.458 | 0.87 (0.41–1.82) | 0.707 | |
| REV3L | rs462779 | TT | Reference | Reference | |||
| p.Thr1224Ile | 0.14 | TC+CC | 2.49 (0.98–6.36) | 0.056 | 2.60 (1.18–5.74) | 0.018 | |
| rs3204953 | GG | Reference | Reference | ||||
| p.Val3064Ile | 0.14 | GA+AA | 0.99 (0.40–2.48) | 0.998 | 1.56 (0.71–3.51) | 0.265 | |
| rs465646 | AA | Reference | Reference | ||||
| c.*461C>T | 0.14 | AG+GG | 1.33 (0.46–3.83) | 0.601 | 1.50 (0.66–3.44) | 0.335 | |
a
p less than 0.010 was considered statistically significant after correction for multiple comparisons; bdata missing for 1 patient.
CI, confidence interval; HR, hazard ratio; MAF, minor allele frequency; OR, odds ratio.